The melanoma driver where BRAF-MEK interaction defines pathway output–and combination therapy addresses resistance.
The RAS-MAPK cascade (RAS'RAF'MEK'ERK) drives proliferation and survival. BRAF is one of three RAF isoforms. The V600E mutation causes constitutive kinase activation independent of upstream RAS signaling.
BRAF signals by phosphorylating MEK1/2, which requires physical BRAF-MEK interaction. This protein-protein interactionLoading... is essential for pathway output and is the basis for combination therapy rationale.
What BRAF Does: BRAF is part of a signaling chain (RAS→RAF→MEK→ERK) that tells cells when to grow. When BRAF is mutated, it's stuck "on" and constantly sends growth signals.
Where It Matters: About half of melanomas have BRAF mutations (especially V600E). They're also found in colorectal, thyroid, and lung cancers.
Single-agent BRAF inhibitors produce dramatic initial responses but resistance develops within 6-8 months. Mechanisms include: MEK mutations, BRAF amplification, RAS mutations, and paradoxical pathway reactivation through RAF dimers.
Combination BRAF+MEK inhibition (dabrafenib/trametinib, encorafenib/binimetinib) delays resistance and improves survival. This combination addresses the BRAF-MEK interaction node directly.
The Challenge: BRAF inhibitors work initially, but resistance develops. Tumors reactivate the pathway through various bypass mechanisms.
Current Approach: Combining BRAF inhibitors with MEK inhibitors delays resistance. But eventually most patients progress.
BRAF inhibitor resistance often involves altered protein-protein interactionsLoading...: RAF dimerization, scaffold protein binding, or feedback loop changes. FRETLoading...-based measurement of BRAF-MEK interaction or pathway output could potentially detect resistance emergence before clinical progression.
This represents an extension of the functional biomarkerLoading... paradigm from checkpoint immunotherapy to targeted therapy.
The Opportunity: BRAF signals through dimerization and protein-protein interactions. Measuring pathway activation state (not just mutation status) could potentially detect emerging resistance.
Connection to QF-Pro: The validated Akt activation assay measures downstream pathway activity, providing one window into BRAF pathway function.
Theoretical Application: BRAF signals through dimerization and downstream pathway activation. While V600E mutation testing guides therapy, functional pathway activation may provide additional predictive information for BRAF/MEK inhibitor response.
Status: Theoretical. BRAF pathway amenable to FRET-based measurement in principle.
Future potential: BRAF V600E mutation testing guides therapy, but functional pathway activation might add predictive value for BRAF/MEK inhibitor response.
